Vincent C.
- Country
- France
- Department
- Department of pneumology
Research Overview
- A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Admilparant in Participants with Idiopathic Pulmonary Fibrosis
- A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Admilparant in Participants with Progressive Pulmonary Fibrosis
- Efficacy and Safety of BI 1015550 in Individuals with Interstitial Lung Abnormalities and a Family History of Pulmonary Fibrosis: A Randomized, Placebo-Controlled Trial
Data & Insights
Has run more than one trial at 292 of 422 partner sites.
Specializations
Pulmonary Hypertension Research
Specializes in the investigation of novel treatments for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension, with particular focus on innovative therapeutic approaches including inhaled and oral medications.
- PAH Treatment Development
- Advanced Stage Disease Management
- Long-term Treatment Outcomes
Interstitial Lung Disease Studies
Conducts research on various forms of interstitial lung disease, including idiopathic pulmonary fibrosis and systemic sclerosis-associated ILD. Focuses on evaluating novel therapeutic agents and combination treatments.
- Progressive Pulmonary Fibrosis
- Systemic Sclerosis Complications
- Therapeutic Innovation
Rare Pulmonary Conditions
Investigates treatments for rare respiratory conditions including autoimmune pulmonary alveolar proteinosis and antisynthetase syndrome-related interstitial lung disease.
- Autoimmune Disorders
- Rare Disease Therapeutics
- Novel Treatment Approaches
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.